ARS Pharmaceuticals’ Q1 2026 update highlights robust uptake of neffy, with over 28,000 healthcare providers having prescribed the product and approximately 120,000 patients currently using it in the U.S. The company continues to expand its sales force and insurance networks, supporting broader access and adoption of its proprietary needle-free intranasal epinephrine spray. Despite operational progress, financial sustainability remains a watchpoint amid ongoing net losses and reliance on third-party manufacturing. Upcoming catalysts include further sales force expansion and clinical trial readouts for pipeline indications.